Allergic Diseases
10
3
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life
n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
Dietary Intervention on Atopy
Systems Biology of Early Atopy
A Study of Single Dose of LP-003 in Adolescent Subjects
Vaginal Microbiome Exposure and Immune Responses in C-section Infants
Biobanking for Biomarkers In Respiratory Disease, Allergic Diseases and/or Mast Cell Disorders
Vitamin D Intervention in Infants - 6 Years Follow-up (VIDI2)
Oral Probiotics to Allergic Pregnant Mother and Their Offspring to Prevent Allergic Disease